

BonAlive Biomaterials Gets CE Mark for BonAlive Putty

□ NOVEMBER 25TH, 2013

● NISHEY WANCHOO

□ ORTHOPEDIC SURGERY



BonAlive Biomaterials Ltd (Turku, Finland) has been awarded CE Mark approval for its BonAlive Putty, a bone graft substitute indicated for treatment of bony voids and gaps. The putty builds on their current osteostimulative S53P4 bioactive glass granules, and combines it with a synthetic binder which dissolves soon after implantation. The bioactive granules develop a silica-gel layer, which promotes calcium phosphate deposition and allows for bonding between the native bone and the granules. With the surface transformed into one that is chemically and structurally similar to the mineral phase of natural bone, osteoblast activity is enhanced, which results in increased bone matrix on the surface of the granules. Bone growth is typically observed within 6 – 12 weeks of implantation.



The putty also increases bone resorption, which results in beneficial bone remodeling. Studies showed similar bone growth at 4 and 8 weeks when comparing the BonAlive putty and BonAlive granules, with highly vascularized and dense bone formation and periosteal growth in both. The putty currently comes in a small applicator size for hand and crano-maxillofacial surgery, and a larger applicator for orthopedic and trauma surgery.

Product page: [BonAlive putty...](#)

Press release: [BonAlive Biomaterials Ltd Receives CE-mark for Osteostimulative BonAlive® Putty...](#)

We recommend

1. [PEEK Orthopedic Implant Uses Stem Cells to Increase Strength and Longevity](#)

Scott Jung, Medgadget, 2012

2. [Electrospun Nanofibers as Orthopedic Scaffolds Help Bones Heal, New Implants Settle In](#)

Editors, Medgadget, 2017

3. [Current Trends and Future Growth of Orthopedic Implants Market](#)

Pawan Pawan, Medgadget, 2017

4. [BioPen to Write Its Way into Surgery Chapter of Regenerative Medicine \(VIDEO\)](#)

Ben Ouyang, Medgadget, 2013

5. [TiO2 Nanotubes For Your Teeth, Better Dental Implants](#)

Yona Gidalevitz, Medgadget, 2013

1. [The Cardio Connection: Cardiovascular Health Influences Ocular Diseases, Study Says](#)

Cardiology Advisor, 2020

2. [Palbociclib with adjuvant endocrine therapy in early breast cancer \(PALLAS\): interim analysis of a multicentre, open-label, randomised, phase 3 study](#)

Mayer EL, et al., Lancet Oncology, 2021

3. [A prospective observational study of patient-reported functioning and quality of life in advanced and metastatic breast cancer utilizing a novel mobile application](#)

Richardson D et al., Breast Cancer Research & Treatment, 2021

4. [Long-Term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis With Up to 5 Years of Follow-Up](#)

Finn RS, et al., Oncologist, 2021

5. [Earlier Age at Menarche Associated With Poorer Cardiovascular Health](#)

Cardiology Advisor, 2020

Powered by

- [Privacy policy](#)
- [Google Analytics settings](#)

I consent to the use of Google Analytics and related cookies across the TrendMD network (widget, website, blog). [Learn more](#)

Yes No